Day: November 22, 2022

Amsterdam, 22 November 2022 – Today, Azerion has announced the acquisition of Radionomy Group, a global pioneer in digital audio advertising and marketing solutions. With this acquisition, Azerion launches a new product in the realm of audio advertising, enabling clients and partners to expand their engagement with users. This acquisition will enhance Azerion’s ability to support advertisers and publishers with a complete suite of advertising products and further solidifies our entry into the US market.

Radionomy has a unique and proprietary adtech solution covering all aspects of digital audio ⎼ including radio, podcasts, audiobooks and games ⎼ and supporting in excess of 3 billion monthly impressions in over 30 markets worldwide. It is connected to a wide range of publishers with more than 15,000 audio channels in aggregate, providing meaningful scale to drive targeted and efficient advertising for advertisers.

Atilla Aytekin, co-CEO of Azerion, comments: “I am excited to add a new suite of audio advertising solutions to our product portfolio and offer more innovative ad formats, from digital radio to in-game audio, helping our advertisers and publishers achieve optimal advertising and monetisation results. As a company that strives to offer a complete set of products to our customers, it is important for us to stay at the forefront of the latest market trends. We are proud to be at the centre of this nascent innovative digital technology that we expect to develop further over the next few years across the United States, Europe, and beyond.”

Azerion has signed a binding transaction documentation relating to the sale of 100% of the issued and outstanding shares in the share capital of Radionomy Group B.V. from Targetspot SA, a company listed on Euronext Growth Paris and Brussels. The transaction perimeter includes Radionomy Group B.V. and all its subsidiaries and, as such, does not include Targetspot’s Winamp operations. Closing of the transaction is subject to certain conditions, including approval by Targetspot’s extraordinary general meeting (EGM), which will be held on 9 December 2022. Closing is expected before 31 December 2022.

The total consideration will be predominantly settled through Azerion shares, with the balance settled in cash. In total, 2,782,644 Azerion shares will be transferred to the selling shareholders at closing of the transaction and such Azerion shares equivalent to up to €3 million are to be granted in future, subject to certain earn-out conditions. Azerion’s shares currently held in treasury are sufficient to satisfy the share consideration. The balance that is payable in cash contains a payment at closing as well as deferred payments. Radionomy is expected to generate approximately €29 million to €30 million gross revenue in 2022.

Radionomy brings together the entire activity of Targetspot with its subsidiaries. The transaction thus involves the indirect disposal of all the subsidiaries of Radionomy Group B.V., the Targetspot and Shoutcast brands and all staff attached to the business.

About Azerion

Azerion is a high-growth digital entertainment and media platform. We entertain people through highly engaging content and we help advertisers reach any audience, at any scale, anywhere in the world in an easy way at a competitive price and in a highquality, curated content environment. Azerion’s integrated platform provides technology solutions to automate the purchase and sale of digital advertising for media buyers and sellers, supported by in-market sales and campaign management teams. Through our technology, content creators, digital publishers and advertisers work with Azerion to reach the hundreds of millions of people across the globe that play Azerion’s games and view its distributed entertainment content to increase engagement, loyalty, and drive e-commerce.

Founded in 2014 by two Dutch entrepreneurs, Azerion has experienced rapid expansion driven by organic growth and strategic acquisitions. Azerion is headquartered in Amsterdam, the Netherlands and is a publicly traded company listed on Euronext Amsterdam. For more information visit: www.azerion.com.

About Targetspot

Targetspot has been a leader and pioneer in digital audio since 2007. Targetspot connects brands to their target audiences via an inventory of leading publishers across all areas of digital audio. Through its proprietary technologies, Targetspot provides end-to-end integration between advertisers and publishers, for contextually targeted, cookie-free campaigns involving both direct and programmatic buying.  Targetspot is also a leader in audio streaming, its Shoutcast brand enabling over 85,000 radio stations to be streamed online. Targetspot is operational in 9 countries and employs around 100 people worldwide.

Contact
Investor Relations
ir@azerion.com

Media
press@azerion.com

GlobeNewswire Distribution ID

SHANGHAI, China, Nov. 22, 2022 (GLOBE NEWSWIRE) — Shanghai Junshi Biosciences Co., Ltd (“Junshi Biosciences”, HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies, announced today that the supplemental application for additional indications of adalimumab injection (project code: UBP1211, trade name: 君邁康®) for the treatment of Crohn’s disease, uveitis, polyarticular juvenile idiopathic arthritis, plaque psoriasis in children and Crohn’s disease in children has been approved by the National Medical Products Administration (“NMPA”).

Tumor necrosis factor-α (TNF-α) is secreted by macrophages, mast cells and activated Th cells. It is a potent inducer of inflammatory response and a key regulator of innate immunity, playing a key role in the occurrence and development of various inflammatory conditions. The binding of TNF-α to TNF-α receptors can induce inflammatory responses, and it has been proven that rheumatoid arthritis, psoriasis, Crohn’s disease, ankylosing spondylitis and many other autoimmune diseases are closely related to TNF-α. Anti-TNF-α monoclonal antibodies can bind to TNF-α receptors and reduce the immune response activated by TNF-α, thereby preventing the occurrence of inflammation.

君迈康 is jointly developed by Junshi Biosciences and Mabwell (Shanghai) Bioscience Co., Ltd. In March 2022, its indications including rheumatoid arthritis, ankylosing spondylitis and psoriasis were approved by the NMPA.

“We are very pleased with the rapid commercialization of 君迈康—since its clinical use less than a year ago, it has already been approved for 8 indications and become one of the domestic adalimumab with the most indications approved in the nation,” said Dr. Ning Li, CEO of Junshi Biosciences. “We will continue collaborating with Mabwell Biosciences to provide more treatment options for a wider range of patients with autoimmune diseases, including children and adults with specific diseases, and further the Healthy China Innitiative with our dedicated efforts.”

“It was wonderful to see 君迈康 achieve 5 indication approvals all at once within a relatively short amount of time,” said Dr. Datao Liu, co-founder and CEO of Mabwell Bioscience. “To this day, many patients in China are still suffering from autoimmune diseases, which severely affect their physical functions and quality of life. The extension of 君迈康’s indications will further benefit patients in China as well as the rest of the world, providing them with treatment options that are both more effective and accessible.”

About Uveitis
Non-infectious intermediate, posterior or panuveitis (NIIPPU) is a group of immune-mediated intraocular inflammatory diseases that may cause complications such as synechia, glaucoma, cataracts, macular edema and retinopathy in patients, causing impaired vision or even blindness, and usually co-occurs with immune-mediated systemic diseases such as psoriasis and ankylosing spondylitis. According to the epidemiological research data in mainland China, its incidence rate is 152/100,000, and the incidence peaks at 24 to 44 years old.

About Crohn’s Disease
It is a chronic and relapsing inflammatory gastrointestinal disease, which is categorized as inflammatory bowel disease (IBD) together with ulcerative colitis (UC). In China, the prevalence rate of Crohn’s disease is 2.29/100,000, the average incidence rate is 1.21/100,000, and it is showing a rapid upward trend. There is currently no complete cure for Crohn’s disease. The goal of treatment is to induce and sustain remission, prevent complications, and improve quality of life.

About Crohn’s Disease in Children
According to statistics, 25% to 30% of all IBD patients in the world are children, of which Crohn’s disease accounts for the vast majority, and its incidence rate has been increasing year by year.

About Polyarticular Juvenile Idiopathic Arthritis
Juvenile idiopathic arthritis is a common rheumatic disease in childhood, with chronic joint synovitis as its main symptom. Accompanied by systemic multiple organ dysfunction, it is also an important cause of childhood disability and blindness. Polyarticular juvenile idiopathic arthritis is the most common subtype of juvenile idiopathic arthritis, accounting for about 18% to 30%.

About Plaque Psoriasis in Children
Pediatric psoriasis is an immune-mediated chronic, recurrent, inflammatory, systemic disease that occurs in children. Different populations, races, and genders are equally susceptible, and about 1/3 of patients have onset of psoriasis in childhood. The common type of psoriasis in older children is plaque psoriasis (75%), followed by guttate psoriasis (15% to 30%) and generalized pustular psoriasis (1% to 5.4%).

About Junshi Biosciences
Founded in December 2012, Junshi Biosciences (HKEX: 1877; SSE: 688180) is an innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization of innovative therapeutics. The company has established a diversified R&D pipeline comprising over 50 drug candidates, with five therapeutic focus areas covering cancer, autoimmune, metabolic, neurological, and infectious diseases. Junshi Biosciences was the first Chinese pharmaceutical company that obtained marketing approval for anti-PD-1 monoclonal antibody in China. Its first-in-human anti-BTLA monoclonal antibody for the treatment of various cancers was the first in the world to be approved for clinical trials by the FDA and NMPA and has since entered Phase Ib/II trials in both China and the US. Its anti-PCSK9 monoclonal antibody was the first in China to be approved for clinical trials by the NMPA.

In the face of the pandemic, Junshi Biosciences’ response was strong and immediate, joining forces with Chinese and international scientific research institutions and enterprises to develop an arsenal of drug candidates to combat COVID-19, taking the initiative to shoulder the social responsibility of Chinese pharmaceutical companies by prioritizing and accelerating COVID-19 R&D. Among the many drug candidates is JS016 (etesevimab), China’s first neutralizing fully human monoclonal antibody against SARS-CoV-2 and the result of the combined efforts of Junshi Biosciences, the Institute of Microbiology of the Chinese Academy of Science and Lilly. JS016 administered with bamlanivimab has been granted Emergency Use Authorizations (EUA) in over 15 countries and regions worldwide. Meanwhile, VV116, a new oral nucleoside analog anti-SARS-CoV-2 drug designed to hinder virus replication, is in global Phase III clinical trials. The JS016 and VV116 programs are a part of the company’s continuous innovation for disease control and prevention of the global pandemic.

Junshi Biosciences has more than 3,100 employees in the United States (San Francisco and Maryland) and China (Shanghai, Suzhou, Beijing and Guangzhou). For more information, please visit: http://junshipharma.com.

Junshi Biosciences Contact Information
IR Team:
Junshi Biosciences
info@junshipharma.com
+ 86 021-6105 8800

PR Team:
Junshi Biosciences
Zhi Li
zhi_li@junshipharma.com
+ 86 021-6105 8800

GlobeNewswire Distribution ID 8701606

VILNIUS, Lithuania, Nov. 21, 2022 (GLOBE NEWSWIRE) — With 12 years of market experience under its belt already, Locatory.com is not slowing down. The aviation marketplace for aircraft spare parts and repair capabilities and a family member of Avia Solutions Group, leaders in end-to-end capacity solutions for passenger and cargo airlines worldwide, is talking about its place in the aviation industry and growth plans.

Since its development in 2010, Locatory.com has become one of the leading premium aircraft parts marketplaces in the world, with the userbase growing 20% each month. “We have been seeing steady growth for a few years now,” shared Toma Matutyte, CEO of Locatory.com. “This increase in clientele interest has been driven by the continuous expansion of our spare parts database. Each month it grows by 15% allowing for a wider variety of parts available. And with cost optimization and sustainability on everyone’s mind, the secondary aviation parts market is becoming an increasingly attractive opportunity. In 2022, we have received 5 times more RFQs (Request for Quotes) when compared to last year and are expecting this trend to continue into the next year.”

As a tool for simplified procurement of spare parts, Locatory.com is deeply invested in the digitalisation of the process. “Our mission is to connect aircraft parts’ buyers and sellers, through seamless transactions via an innovative platform that enables our customers to find, buy, and sell aircraft parts or repair services in commercial, OEM, MRO, military, and general aviation segments across the globe,” she explained. “We are focusing on innovation and efficiency therefore we have already successfully introduced a range of innovative features to our marketplace. Amber, the A.I.-based assistant, being one of them.”

Running a well-oiled online marketplace is not an easy task, thus having a strong team behind you is a must. “We have a truly global team, with people from over 10 countries sharing ideas and expertise in improving the company. We have been steadily expanding by around 15 % each month and there are no plans of slowing down,” she said.

By keeping innovation and optimisation as the main driving factors, Locatory.com is constantly working on keeping up and surpassing the ever-changing aviation industry needs. “Improving spare aircraft parts procurement processes can positively impact the whole aviation industry thus we will continue creating tools to do so,” said Toma Matutyte.

Vilma Vaitiekunaite
Chief Communications Officer
Cell: +37061112789
E-mail: Vilma.Vaitiekunaite@aviasg.com

GlobeNewswire Distribution ID 1000768118